PMID- 27272964
OWN - NLM
STAT- MEDLINE
DCOM- 20170418
LR  - 20170418
IS  - 1098-9064 (Electronic)
IS  - 0094-6176 (Linking)
VI  - 43
IP  - 3
DP  - 2017 Apr
TI  - Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin 
      Therapy: Issues and Recommendations.
PG  - 253-260
LID - 10.1055/s-0036-1581128 [doi]
AB  - When administering unfractionated heparin (UFH), therapeutic levels of 
      anticoagulation must be achieved rapidly and maintained consistently in the 
      therapeutic range. The basic assays for monitoring UFH therapy are the activated 
      partial thromboplastin time (APTT) and/or the chromogenic antifactor Xa or 
      antithrombin assays. For many laboratories, the APTT is the preferred standard of 
      practice; however, the APTT is a surrogate marker that only estimates the heparin 
      concentration. Many factors, including patient variation, reagents of the APTT, 
      UFH composition, and concentration can influence the APTT result. This article 
      reviews various methods to determine the heparin therapeutic range and presents 
      recommendations for the laboratory to establish an APTT heparin therapeutic range 
      for all sizes of hospitals.
CI  - Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
FAU - Marlar, Richard A
AU  - Marlar RA
AD  - Pathology and Laboratory Medicine Service, Oklahoma City VA Health Care System, 
      Oklahoma City, Oklahoma.
FAU - Clement, Bernadette
AU  - Clement B
AD  - College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma 
      City, Oklahoma.
FAU - Gausman, Jana
AU  - Gausman J
AD  - Pathology and Laboratory Medicine Service, Oklahoma City VA Health Care System, 
      Oklahoma City, Oklahoma.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160606
PL  - United States
TA  - Semin Thromb Hemost
JT  - Seminars in thrombosis and hemostasis
JID - 0431155
RN  - 0 (Anticoagulants)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/blood/therapeutic use
MH  - Blood Coagulation
MH  - Drug Monitoring/*methods
MH  - Guidelines as Topic
MH  - Heparin/blood/*therapeutic use
MH  - Humans
MH  - Partial Thromboplastin Time/*methods/standards
MH  - Reference Values
MH  - Reproducibility of Results
MH  - Venous Thromboembolism/blood/*prevention & control
EDAT- 2016/06/09 06:00
MHDA- 2017/04/19 06:00
CRDT- 2016/06/09 06:00
PHST- 2016/06/09 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PHST- 2016/06/09 06:00 [entrez]
AID - 10.1055/s-0036-1581128 [doi]
PST - ppublish
SO  - Semin Thromb Hemost. 2017 Apr;43(3):253-260. doi: 10.1055/s-0036-1581128. Epub 
      2016 Jun 6.